AnaptysBio’s (ANAB) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of AnaptysBio (NASDAQ:ANABFree Report) in a research note released on Tuesday, MarketBeat Ratings reports. They currently have a $45.00 price objective on the biotechnology company’s stock.

Several other research firms have also issued reports on ANAB. HC Wainwright upgraded shares of AnaptysBio from a “neutral” rating to a “buy” rating and upped their target price for the stock from $22.00 to $38.00 in a research note on Wednesday, June 4th. JPMorgan Chase & Co. upped their price objective on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Finally, UBS Group reissued a “neutral” rating and set a $20.00 target price (up previously from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average target price of $48.75.

Check Out Our Latest Stock Report on AnaptysBio

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $31.34 on Tuesday. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $36.54. The stock has a market capitalization of $877.52 million, a P/E ratio of -7.00 and a beta of -0.18. The company has a 50-day moving average price of $22.34 and a 200-day moving average price of $21.74.

AnaptysBio (NASDAQ:ANABGet Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%.The business had revenue of $22.26 million during the quarter, compared to the consensus estimate of $11.55 million. As a group, equities research analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. US Bancorp DE lifted its holdings in AnaptysBio by 126.5% during the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 979 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of AnaptysBio by 9,778.9% during the 1st quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,858 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares in the last quarter. Osaic Holdings Inc. grew its stake in AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 2,326 shares in the last quarter. Finally, GAMMA Investing LLC bought a new stake in AnaptysBio during the 1st quarter valued at $113,000.

About AnaptysBio

(Get Free Report)

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

Featured Articles

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.